Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or MDR1A/1B (-/-) mice

Drug Metabolism and Disposition

Volumn 33, Issue 3, 2005, Pages 341-348

  Zhang, Shuzhong ^a   Wang, Xiaodong ^a   Sagawa, Kazuko ^b   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOFLAVONE DERIVATIVE; BREAST CANCER RESISTANCE PROTEIN; CHRYSIN; ELACRIDAR; FLAVONOID; FUMITREMORGIN C; MITOXANTRONE; PROTEIN INHIBITOR; TOPOTECAN; UNCLASSIFIED DRUG; VALSPODAR;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TRANSPORT; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE;

ACRIDINES; ANIMALS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; BENZOFLAVONES; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; DRUG INTERACTIONS; FEMALE; FLAVONOIDS; HUMANS; MALE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; P-GLYCOPROTEINS; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROISOQUINOLINES; TOPOTECAN;

EID: 14044269476     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.002501     Document Type: Article

References (41)

1. Achira M, Suzuki H, Ito K, and Sugiyama Y (1999) Comparative studies to determine the selective inhibitors for P-glycoprotein and cytochrome P4503A4. AAPS PharmSci 1:E18.
2. Allen JD, Brinkhuis RF, Wijnholds J, and Schinkel AH (1999) The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res 59:4237-4241.
3. Chen HY, Wu TS, Su SF, Kuo SC, and Chao PD (2002) Marked decrease of cyclosporin absorption caused by phellamurin in rats. Planta Med 68:138-141.
4. Chen J and Balthasar JP (2002) Determination of topotecan in mouse plasma by high-performance liquid chromatographic assay (Abstract). AAPS PharmSci 4:W4012.
5. Choi JS, Choi HK, and Shin SC (2004a) Enhanced bioavailability of paclitaxel after oral coadministration with flavone in rats. Int J Pharm 275:165-170.
6. Choi JS, Jo BW, and Kim YC (2004b) Enhanced paclitaxel bioavailability after oral administration of paclitaxel or prodrug to rats pretreated with quercetin. Eur J Pharm Biopharm 57:313-318.
7. Conseil G, Baubichon-Cortay H, Dayan G, Jault JM, Barron D, and Di Pietro A (1998) Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP- and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci USA 95:9831-9836.
8. Cooray HC, Blackmore CG, Maskell L, and Barrand MA (2002) Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 13:2059-2063.
9. Cooray HC, Janvilisri T, van Veen HW, Hladky SB, and Barrand MA (2004) Interaction of the breast cancer resistance protein with plant polyphenols. Biochem Biophys Res Commun 317:269-275.
10. Dennis MJ, Beijnen JH, Grochow LB, and van Warmerdam LJ (1997) An overview of the clinical pharmacology of topotecan. Semin Oncol 24:S5-12-S15-18.
11. Doyle LA and Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340-7358.
12. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, and Kim RB (2002) Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 71:11-20.
13. Galijatovic A, Otake Y, Walle UK, and Walle T (1999) Extensive metabolism of the flavonoid chrysin by human Caco-2 and Hep G2 cells. Xenobiotica 29:1241-1256.
14. Havsteen BH (2002) The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96:67-202.
15. Hertog MG, Feskens EJ, Hollman PC, Katan MB, and Kromhout D (1993) Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 342:1007-1011.
16. Ho PC, Saville DJ, and Wanwimolruk S (2001) Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 4:217-227.
17. Hsiu SL, Hou YC, Wang YH, Tsao CW, Su SF, and Chao PD (2002) Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. Life Sci 72:227-235.
18. Imai Y, Tsukahara S, Asada S, and Sugimoto Y (2004) Phytoestrogens/ flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res 64:4346-4352.
19. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, and Schinkel AH (2000) Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656.
20. Kruijtzer CM, Beijnen JH, Rosing H, ten Bokkel Huinink WW, Schot M, Jewell RC, Paul EM, and Schellens JH (2002) Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20: 2943-2950.
21. Kuhnau J (1976) The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet 24:117-191.
22. Litman T, Druley TE, Stein WD, and Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959.
23. Lohr JW, Willsky GR, and Acara MA (1998) Renal drug metabolism. Pharmacol Rev 50:107-141.
24. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, and Schellens JH (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61:3458-3464.
25. Middleton E Jr, Kandaswami C, and Theoharides TC (2000) The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52:673-751.
26. Murota K, Shimizu S, Chujo H, Moon JH, and Terao J (2000) Efficiency of absorption and metabolic conversion of quercetin and its glucosides in human intestinal cell line Caco-2. Arch Biochem Biophys 384:391-397.
27. Nguyen H, Zhang S, and Morris ME (2003) Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 92:250-257.
28. Platzer P, Schaden S, Thalhammer T, Hamilton G, Rosenberg B, Silgoner I, and Jager W (1998) Biotransformation of topotecan in the isolated perfused rat liver: identification of three novel metabolites. Anticancer Res 18:2695-2700.
29. Rabindran SK, He H, Singh M, Brown E, Collins KI, Annable T, and Greenberger LM (1998) Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C. Cancer Res 58:5850-5858.
30. Robey RW, Honjo Y, Morisaki K, Nadjem TA, Runge S, Risbood M, Poruchynsky MS, and Bates SE (2003) Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br J Cancer 89:1971-1978.
31. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, and Bates SE (2004) Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64:1242-1246.
32. Rosing H, Herben VM, van Gortel-van Zomeren DM, Hop E, Kettenes-van den Bosch JJ, ten Bokkel Huinink WW, and Beijnen JH (1997) Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan. Cancer Chemother Pharmacol 39:498-504.
33. Rosing H, van Zomeren DM, Doyle E, ten Bokkel WW, Schellens JH, Bult A, and Beijnen JH (1999) Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods. J Chromatogr B Biomed Sci Appl 727:191-203.
34. Ruschitzka F, Meier PJ, Turina M, Luscher TF, and Noll G (2000) Acute heart transplant rejection due to Saint John's wort. Lancet 355:548-549.
35. Steinbach D, Sell W, Voigt A, Hermann J, Zintl F, and Sauerbrey A (2002) BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia (Baltimore) 16:1443-1447.
36. Underberg WJ, Goossen RM, Smith BR, and Beijnen JH (1990) Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 8:681-683.
37. Walle UK, Galijatovic A, and Walle T (1999) Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem Pharmacol 58:431-438.
38. Zamboni WC, Houghton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Luo X, and Stewart CF (1998) Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J Pharmacol Exp Ther 284:89-94.
39. Zhang S and Morris ME (2003) Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res (NY) 20:1184-1191.
40. Zhang S, Yang X, and Morris ME (2004a) Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res (NY) 21:1263-1273.
41. Zhang S, Yang X, and Morris ME (2004b) Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65:1208-1216.